MedTrace Logo

A Study Comparing the Effects of Trimbow to Fostair in COPD

NCT03842904 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-01-27

No results posted yet for this study

Summary

A randomised, open label 2-way cross-over study to compare the effects of inhaled Beclometasone/Formoterol/Glycopyrronium (TRIMBOW) pMDI to Beclometasone/Formoterol (FOSTAIR) pMDI on hyperinflation and expiratory flow limitation in moderate to severe chronic obstructive pulmonary disease (COPD).

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Trimbow pMDI

Clinical Trial of an Investigational Medicinal Product (CTIMP)

DRUG

Fostair pMDI

Clinical Trial of an Investigational Medicinal Product (CTIMP)

Sponsors & Collaborators

  • Chiesi UK

    collaborator INDUSTRY

  • Medicines Evaluation Unit Ltd

    lead INDUSTRY

Principal Investigators

  • David Rogers · Medicines Evaluation Unit Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-13
Primary Completion
2019-07-30
Completion
2019-08-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03842904 on ClinicalTrials.gov